Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC22 Combined With Peg-IFNa in Chronic Hepatitis B
NCT07573943Phase 4Recruiting
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- May 2024
- Primary completion
- Dec 2026
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label trial of envafolimab in Chronic Hepatitis B (CHB) (3 cohorts), sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoints: Serum Hepatitis B surface antigen at 72 weeks, Serum HBV DNA at 72 weeks and 1 more. Started May 2024; status: recruiting.
02
Drugs
envafolimab
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07573943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07573943.